Cervical cancer
Conditions
Interventions
Case series:concurrent chemoradiotherapy with recombinant human endostatin
Sponsors
Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. histologically confirmed squamous cell carcinoma of the cervix; 3. FIGO stage IIB-IVA, with retroperitoneal lymph node metastases; 4. KPS score =70; 5. With at least one measurable lesion (RECIST 1.1 criteria); 6. life expectancy not less than 6 months; 7. WBC=4x10^9/L, ANC=1.5x10^9/L, HB=90g/L, PLT=100x10^9/L. Adequate hepatic and renal function; 8. Patient is able to provide signed informed consent; 9. patient willing to complete follow-up.
Exclusion criteria
Exclusion criteria: 1. distant metastases; 2. Combined with other malignant tumors; 3. Previously treated with antitumor therapy, such as radiation, chemotherapy or target therapy; 4. Contraindications to chemoradiotherapy, including severe infection or other complications such as coronary heart disease within 6 months, severe arrhythmia, severe cerebrovascular disease, mental illness and uncontrolled diabetes; 5. With uncontrolled hypertension, hypertensive crisis or hypertensive encephalopathy before enrollment; 6. Seizures need to be treated; 7. Vaginal bleeding within 6 months (blood transfusion required); 8. Allergy to recombinant human endostatin; 9. Pregnancy and lactation. Pregnancy test results were positive for women of reproductive age within 14 days before enrollment; 10. Participating in other studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year PFS; | — |
Countries
China
Contacts
Public ContactXiaofan Li, Xing Su
Peking University Cancer Hospital
Outcome results
None listed